PHASE I DOSE-ESCALATION STUDY OF THE MULTIKINASE INHIBITOR LENVATINIB IN PATIENTS WITH ADVANCED SOLID TUMORS AND IN AN EXPANDED COHORT OF PATIENTS WITH MELANOMA

Sunday, July 26, 2015

Read the Story Here

Related Posts

Discover more posts like this.

A biomarker signature differentiates immune status in patients with cold gastrointestinal tumors, predicting clinical benefit of NT-I7 (efineptakin alfa, a long-acting interleukin-7) and pembrolizumab

Dec 17, 2024

Utilizing pharmacokinetic (PK) and pharmacodynamic (PD) biomarkers to support recommended Phase 2 dose (RP2D) selection for Phase 1 study of SAR444245 (SAR’245) in patients with advanced solid tumors

Dec 17, 2024

Trial in progress: A first-in-human phase 1a/b, dose-escalation/expansion study of BG-68501/ETX-197 (CDK2 inhibitor) as monotherapy or in combination with fulvestrant for patients with HR+/HER2− breast cancer and other advanced solid tumors

Dec 17, 2024
See All Posts